Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 179

1.

Metabotropic glutamate receptors, 5 years on.

Collingridge GL, Manahan-Vaughan D, Nicoletti F, Schoepp DD.

Neuropharmacology. 2017 Mar 15;115:1-3. doi: 10.1016/j.neuropharm.2016.09.029. Epub 2016 Nov 29. No abstract available.

PMID:
27908770
2.

The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits.

Witkin JM, Monn JA, Schoepp DD, Li X, Overshiner C, Mitchell SN, Carter G, Johnson B, Rasmussen K, Rorick-Kehn LM.

J Pharmacol Exp Ther. 2016 Jul;358(1):71-82. doi: 10.1124/jpet.116.233627. Epub 2016 May 12.

PMID:
27189960
3.

Alzheimer's disease research and development: a call for a new research roadmap.

Feldman HH, Haas M, Gandy S, Schoepp DD, Cross AJ, Mayeux R, Sperling RA, Fillit H, van de Hoef DL, Dougal S, Nye JS; One Mind for Research and the New York Academy of Sciences.

Ann N Y Acad Sci. 2014 Apr;1313:1-16. doi: 10.1111/nyas.12424.

PMID:
24754377
4.

CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [³H]LY459477 autoradiography.

Wright RA, Johnson BG, Zhang C, Salhoff C, Kingston AE, Calligaro DO, Monn JA, Schoepp DD, Marek GJ.

Neuropharmacology. 2013 Mar;66:89-98. doi: 10.1016/j.neuropharm.2012.01.019. Epub 2012 Jan 31.

PMID:
22313530
5.

Where will new neuroscience therapies come from?

Schoepp DD.

Nat Rev Drug Discov. 2011 Sep 30;10(10):715-6. doi: 10.1038/nrd3559.

PMID:
21959271
6.

Metabotropic glutamate receptors: from the workbench to the bedside.

Nicoletti F, Bockaert J, Collingridge GL, Conn PJ, Ferraguti F, Schoepp DD, Wroblewski JT, Pin JP.

Neuropharmacology. 2011 Jun;60(7-8):1017-41. doi: 10.1016/j.neuropharm.2010.10.022. Epub 2010 Oct 29. Review.

7.

Use of MGLUR2 and MGLUR3 knockout mice to explore in vivo receptor specificity of the MGLUR2/3 selective antagonist LY341495.

Linden AM, Johnson BG, Trokovic N, Korpi ER, Schoepp DD.

Neuropharmacology. 2009 Aug;57(2):172-82. doi: 10.1016/j.neuropharm.2009.05.002. Epub 2009 May 27.

PMID:
19477188
8.
9.

Schizophrenia: moving beyond monoamine antagonists.

Conn PJ, Tamminga C, Schoepp DD, Lindsley C.

Mol Interv. 2008 Apr;8(2):99-107. doi: 10.1124/mi.8.2.7. Review.

PMID:
18403654
10.

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.

Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD.

Nat Med. 2007 Sep;13(9):1102-7. Epub 2007 Sep 2. Erratum in: Nat Med. 2007 Oct;13(10):1264.

PMID:
17767166
11.

Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder.

Dunayevich E, Erickson J, Levine L, Landbloom R, Schoepp DD, Tollefson GD.

Neuropsychopharmacology. 2008 Jun;33(7):1603-10. Epub 2007 Aug 22. Erratum in: Neuropsychopharmacology.2008 Sep;33(10):2549.

12.

Metabotropic glutamate receptors in the control of mood disorders.

Witkin JM, Marek GJ, Johnson BG, Schoepp DD.

CNS Neurol Disord Drug Targets. 2007 Apr;6(2):87-100. Review.

PMID:
17430147
13.

In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.

Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, Perry KW, Griffey KI, Tizzano JP, Monn JA, McKinzie DL, Schoepp DD.

Psychopharmacology (Berl). 2007 Jul;193(1):121-36. Epub 2007 Mar 24.

PMID:
17384937
14.

Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors.

Monn JA, Massey SM, Valli MJ, Henry SS, Stephenson GA, Bures M, Hérin M, Catlow J, Giera D, Wright RA, Johnson BG, Andis SL, Kingston A, Schoepp DD.

J Med Chem. 2007 Jan 25;50(2):233-40.

PMID:
17228865
15.

Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).

Rorick-Kehn LM, Johnson BG, Burkey JL, Wright RA, Calligaro DO, Marek GJ, Nisenbaum ES, Catlow JT, Kingston AE, Giera DD, Herin MF, Monn JA, McKinzie DL, Schoepp DD.

J Pharmacol Exp Ther. 2007 Apr;321(1):308-17. Epub 2007 Jan 4.

PMID:
17204749
18.

The metabotropic glutamate 2/3 receptor agonist LY404039 reduces alcohol-seeking but not alcohol self-administration in alcohol-preferring (P) rats.

Rodd ZA, McKinzie DL, Bell RL, McQueen VK, Murphy JM, Schoepp DD, McBride WJ.

Behav Brain Res. 2006 Aug 10;171(2):207-15. Epub 2006 May 6.

PMID:
16678921
19.

Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo.

Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM.

Neuron. 2005 Dec 22;48(6):913-22.

20.

Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344.

Rorick-Kehn LM, Perkins EJ, Knitowski KM, Hart JC, Johnson BG, Schoepp DD, McKinzie DL.

J Pharmacol Exp Ther. 2006 Feb;316(2):905-13. Epub 2005 Oct 13.

PMID:
16223873
21.

C3'-cis-Substituted carboxycyclopropyl glycines as metabotropic glutamate 2/3 receptor agonists: synthesis and SAR studies.

González R, Collado I, de Uralde BL, Marcos A, Martín-Cabrejas LM, Pedregal C, Blanco-Urgoiti J, Pérez-Castells J, Fernández MA, Andis SL, Johnson BG, Wright RA, Schoepp DD, Monn JA.

Bioorg Med Chem. 2005 Dec 1;13(23):6556-70. Epub 2005 Sep 8.

PMID:
16153851
22.

Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist.

Bueno AB, Collado I, de Dios A, Domínguez C, Martín JA, Martín LM, Martínez-Grau MA, Montero C, Pedregal C, Catlow J, Coffey DS, Clay MP, Dantzig AH, Lindstrom T, Monn JA, Jiang H, Schoepp DD, Stratford RE, Tabas LB, Tizzano JP, Wright RA, Herin MF.

J Med Chem. 2005 Aug 11;48(16):5305-20.

PMID:
16078848
23.

Thyrotropin-releasing hormone (protirelin) inhibits potassium-stimulated glutamate and aspartate release from hippocampal slices in vitro.

Nie Y, Schoepp DD, Klaunig JE, Yard M, Lahiri DK, Kubek MJ.

Brain Res. 2005 Aug 23;1054(1):45-54.

PMID:
16055093
25.

Methyl substitution of 2-aminobicyclo[3.1.0]hexane 2,6-dicarboxylate (LY354740) determines functional activity at metabotropic glutamate receptors: identification of a subtype selective mGlu2 receptor agonist.

Dominguez C, Prieto L, Valli MJ, Massey SM, Bures M, Wright RA, Johnson BG, Andis SL, Kingston A, Schoepp DD, Monn JA.

J Med Chem. 2005 May 19;48(10):3605-12.

PMID:
15887967
26.

Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s).

Johnson MP, Barda D, Britton TC, Emkey R, Hornback WJ, Jagdmann GE, McKinzie DL, Nisenbaum ES, Tizzano JP, Schoepp DD.

Psychopharmacology (Berl). 2005 Apr;179(1):271-83. Epub 2005 Feb 17.

PMID:
15717213
27.

Metabotropic glutamate receptors as novel targets for anxiety and stress disorders.

Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, Schoepp DD.

Nat Rev Drug Discov. 2005 Feb;4(2):131-44. Review.

PMID:
15665858
28.

Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice.

Linden AM, Shannon H, Baez M, Yu JL, Koester A, Schoepp DD.

Psychopharmacology (Berl). 2005 Apr;179(1):284-91. Epub 2004 Dec 24.

PMID:
15619115
29.

(2S,1'S,2'R,3'R)-2(2'-Carboxy-3'-hydroxymethylcyclopropyl)glycine-[3H], a potent and selective radioligand for labeling group 2 and 3 metabotropic glutamate receptors.

Wheeler WJ, Clodfelter DK, Collado I, Kulanthaivel P, Pedregal C, Stoddard EA, Wright RA, Schoepp DD.

Bioorg Med Chem Lett. 2005 Jan 17;15(2):349-51.

PMID:
15603952
30.

Effects of LY354740, a novel glutamatergic metabotropic agonist, on nonhuman primate hypothalamic-pituitary-adrenal axis and noradrenergic function.

Coplan JD, Mathew SJ, Smith EL, Trost RC, Scharf BA, Martinez J, Gorman JM, Monn JA, Schoepp DD, Rosenblum LA.

CNS Spectr. 2001 Jul;6(7):607-12, 617.

PMID:
15573025
31.

Glutamate-hypothalamic-pituitary-adrenal axis interactions: implications for mood and anxiety disorders.

Mathew SJ, Coplan JD, Schoepp DD, Smith EL, Rosenblum LA, Gorman JM.

CNS Spectr. 2001 Jul;6(7):555-6, 561-4.

PMID:
15573019
32.

The mGlu2/3 receptor agonist LY379268 injected into cortex or thalamus decreases neuronal injury in retrosplenial cortex produced by NMDA receptor antagonist MK-801: possible implications for psychosis.

Carter K, Dickerson J, Schoepp DD, Reilly M, Herring N, Williams J, Sallee FR, Sharp JW, Sharp FR.

Neuropharmacology. 2004 Dec;47(8):1135-45.

PMID:
15567423
34.

SAR study of a subtype selective allosteric potentiator of metabotropic glutamate 2 receptor, N-(4-phenoxyphenyl)-N-(3-pyridinylmethyl)ethanesulfonamide.

Barda DA, Wang ZQ, Britton TC, Henry SS, Jagdmann GE, Coleman DS, Johnson MP, Andis SL, Schoepp DD.

Bioorg Med Chem Lett. 2004 Jun 21;14(12):3099-102.

PMID:
15149652
35.

(2S,1'S,2'R,3'R)-2-(2'-Carboxy-3'-hydroxymethylcyclopropyl) glycine is a highly potent group 2 and 3 metabotropic glutamate receptor agonist with oral activity.

Collado I, Pedregal C, Bueno AB, Marcos A, González R, Blanco-Urgoiti J, Pérez-Castells J, Schoepp DD, Wright RA, Johnson BG, Kingston AE, Moher ED, Hoard DW, Griffey KI, Tizzano JP.

J Med Chem. 2004 Jan 15;47(2):456-66.

PMID:
14711315
37.
39.

LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress.

Schoepp DD, Wright RA, Levine LR, Gaydos B, Potter WZ.

Stress. 2003 Sep;6(3):189-97. Review.

PMID:
13129812
42.

Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine.

Johnson MP, Baez M, Jagdmann GE Jr, Britton TC, Large TH, Callagaro DO, Tizzano JP, Monn JA, Schoepp DD.

J Med Chem. 2003 Jul 17;46(15):3189-92.

PMID:
12852748
43.

Evaluation of [3H]LY341495 for labeling group II metabotropic glutamate receptors in vivo.

Waterhouse RN, Schmidt ME, Sultana A, Schoepp DD, Wheeler WJ, Mozley PD, Laruelle M.

Nucl Med Biol. 2003 Feb;30(2):187-90.

PMID:
12623118
44.

Synthesis and structure-activity relationship studies of novel 2-diarylethyl substituted (2-carboxycycloprop-1-yl)glycines as high-affinity group II metabotropic glutamate receptor ligands.

Sørensen US, Bleisch TJ, Kingston AE, Wright RA, Johnson BG, Schoepp DD, Ornstein PL.

Bioorg Med Chem. 2003 Jan 17;11(2):197-205.

PMID:
12470714
46.

Metabotropic glutamate receptors.

Schoepp DD, Conn PJ.

Pharmacol Biochem Behav. 2002 Dec;74(1):255-6. No abstract available.

PMID:
12376174
47.

Inhibition of group I metabotropic glutamate receptor responses in vivo in rats by a new generation of carboxyphenylglycine-like amino acid antagonists.

Kingston AE, Griffey K, Johnson MP, Chamberlain MJ, Kelly G, Tomlinson R, Wright RA, Johnson BG, Schoepp DD, Harris JR, Clark BP, Baker RS, Tizzano JT.

Neurosci Lett. 2002 Sep 20;330(2):127-30.

PMID:
12231428
48.

Increased anxiety-related behavior in mice deficient for metabotropic glutamate 8 (mGlu8) receptor.

Linden AM, Johnson BG, Peters SC, Shannon HE, Tian M, Wang Y, Yu JL, Köster A, Baez M, Schoepp DD.

Neuropharmacology. 2002 Aug;43(2):251-9.

PMID:
12213279
49.

(2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 receptor agonist with anxiolytic properties.

Collado I, Pedregal C, Mazón A, Espinosa JF, Blanco-Urgoiti J, Schoepp DD, Wright RA, Johnson BG, Kingston AE.

J Med Chem. 2002 Aug 15;45(17):3619-29.

PMID:
12166935
50.

The selective group mGlu2/3 receptor agonist LY379268 suppresses REM sleep and fast EEG in the rat.

Feinberg I, Campbell IG, Schoepp DD, Anderson K.

Pharmacol Biochem Behav. 2002 Sep;73(2):467-74.

PMID:
12117602

Supplemental Content

Loading ...
Support Center